Bevacizumab is a recombinant humanized monoclonal antibody that prevents vascular endothelial growth factor-A (VEGF-A) from having its physiological effect (an essential endothelial cell mitogen and survival factor). It is the first anti-angiogenic drug to be given the green light for use in the treatment of human cancer. The drug was created by F. Hoffmann-La Roche AG and received US Food and Drug Administration (FDA) approval in February 2004 as a first-line therapy for the treatment of metastatic colorectal cancer when is associated with intravenous chemotherapy based on 5-fluorouracil. In the United States and Europe, bevacizumab has been approved for use in the treatment of patients with cancer of the cervix, epithelial ovary, or fallopian tubes. Bevacizumab is also licensed for the treatment of people with non-small cell lung cancer or renal cell carcinoma that has spread. Additionally, it is approved for use in the treatment of glioblastoma patients in the United States, and it is approved for use in the treatment of metastatic breast cancer in Europe. Bevacizumab received the green light from the European Medicines Agency in 2005 and is now sold under the brand name Avastin.
Request for sample pages:
Teva Pharmaceutical Industries
and among others.
Global Bevacizumab Biosimilars Market SegmentationGlobal Bevacizumab Biosimilars Market Outlook (Revenue, USD Million, 2019-2030) by Product
Other clinical trial products
Global Bevacizumab Biosimilar Market Outlook (Revenue, USD Million, 2019 – 2030) by Application
Non-small cell lung cancer
Renal cell carcinoma
Global Bevacizumab Biosimilar Market Outlook (Revenue, USD Million, 2019 – 2030) by Distribution Channel
Other direct distribution channels
For more information :
InsightAce Analytic is a market research and consulting company that empowers clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market intelligence and competition to grow businesses. We help our clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in delivering syndicated and customized market intelligence reports with in-depth analysis with key market insights in a timely and cost effective manner.
InsightAce Analytics Pvt. ltd.
Such. : +1 551 226 6109
Email: [email protected]
Site visit: www.insightaceanalytic.com
Follow us on LinkedIn @ bit.ly/2tBXsgS
Follow us on Facebook @ bit.ly/2H9jnDZ